GRASSLEY USES ALLEGED WYETH DISPUTE TO CALL FOR CHANGE IN FDA LEADERSHIP
Sen. Chuck Grassley (R-Iowa), chairman of the Finance Committee and an increasingly
vocal critic of the FDA, is using an alleged effort by Wyeth to discredit an
agency investigator as ammunition in his campaign to reform the agency's relationship
with the pharmaceutical industry and to bolster his call for a permanent, reform-minded
commissioner.
Grassley recently argued on the Senate floor that a recent dispute in which
the FDA undertook a criminal investigation of one of its employees in response
to an industry complaint about potential conflict of interest is further evidence
that the agency remains deeply flawed.
Last year, former FDA Commissioner Lester Crawford met with Wyeth CEO Robert
Essner to address the company's concerns that an agency reviewer that had criticized
one of its veterinary medicines had personal and financial conflicts of interest,
according to Grassley. After the meeting Crawford reassigned the staffer, Victoria
Hampshire, and launched a criminal investigation against her. That investigation
turned up no evidence of wrongdoing, according to Grassley.
Crawford's actions show that the agency is too close to the industry it is supposed
to be regulating, Grassley said. "So, a year later, we are still uncovering
the cozy relationship between the agency and the drug industry," he said.
"Dr. Hampshire's sad story is further proof that the FDA needs a permanent
commissioner who can restore order and respect for independence. The Food and
Drug Administration cannot serve the American people and the interests of the
drug industry at the same time."
Grassley argued that the first step in ensuring that the FDA is independent
is to appoint a full-time commissioner, who is committed to reforming the agency.
"This leader must recognize the problems of a culture that's become too
cozy with the industry," he said. "Then that leader must be tough
enough to make necessary changes happen." Grassley also pledged to continue
to push two FDA reform bills in the Senate, the Fair Access to Clinical Trials
Act and the Food and Drug Administration Safety Act of 2005.
Grassley is also targeting Wyeth for its efforts to "discredit" Hampshire
and have her reassigned. In a recent letter to Essner, the senator demands that
the company provide information concerning its actions, including: an explanation
of how the company concluded that Hampshire had a conflict of interest; the
names of all people who were involved in the company's investigation; and how
many times the company has investigated agency employees.
The company intends to comply with Grassley's request and maintains that it
did nothing wrong, Wyeth spokesman Douglas Petkus told FDAnews "The company
believes that we have always acted responsibly and appropriately in all respects
regarding this matter," he said.